Acumen Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Acumen Pharmaceuticals, Inc. (ABOS) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $5.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$2.19M.
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$5.47M.
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$19.95M.
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$52.10M.
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $18.36M.
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$31.26M.
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$62.98M, a 893.32% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $7.94M, a 89.87% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.45M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$2.19M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $18.36M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $11.21M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.18M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$5.47M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$31.26M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | -$33.70M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $1.07M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$19.95M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$62.98M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$34.99M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$52.85M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$52.10M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $7.94M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $35.38M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$11.10M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$13.40M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $78.39M 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $92.03M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $25.04M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$2.37M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $37.23M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | -$4.59M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$3.31M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |